MDxHealth SA ADR Net Assets
MDxHealth SA ADR net assets. Based on the latest financial reports, MDxHealth SA ADR (MDXH) has net assets worth $-30.40 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($132.09 Million) and total liabilities ($162.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore MDxHealth SA ADR equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-30.40 Million |
| % of Total Assets | -23.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | -125.79% |
| 10-Year Change | -122.93% |
| Growth Volatility | 169.91 |
Net Assets of MDxHealth SA ADR (2004–2025)
Net assets of MDxHealth SA ADR from 2004 to 2025. This chart illustrates how MDxHealth SA ADR's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of MDxHealth SA ADR to measure how much of total assets are equity-financed.
Annual Net Assets for MDxHealth SA ADR (2004–2025)
The table below shows the annual net assets of MDxHealth SA ADR from 2004 to 2025. For live market cap and overall valuation, see MDxHealth SA ADR market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-12.09 Million | -181.49% |
| 2024-12-31 | $14.84 Million | +105.90% |
| 2023-12-31 | $7.21 Million | -22.62% |
| 2022-12-31 | $9.31 Million | -80.14% |
| 2021-12-31 | $46.90 Million | +701.83% |
| 2020-12-31 | $5.85 Million | -70.35% |
| 2019-12-31 | $19.72 Million | -62.15% |
| 2018-12-31 | $52.12 Million | +19.68% |
| 2017-12-31 | $43.55 Million | -17.43% |
| 2016-12-31 | $52.74 Million | +19.16% |
| 2015-12-31 | $44.26 Million | +86.16% |
| 2014-12-31 | $23.78 Million | -3.10% |
| 2013-12-31 | $24.54 Million | +53.12% |
| 2012-12-31 | $16.02 Million | +9.22% |
| 2011-12-31 | $14.67 Million | +2.88% |
| 2010-12-31 | $14.26 Million | -47.05% |
| 2009-12-31 | $26.94 Million | -40.73% |
| 2008-12-31 | $45.44 Million | -8.66% |
| 2007-12-31 | $49.75 Million | +17.87% |
| 2006-12-31 | $42.21 Million | +253.22% |
| 2005-12-31 | $11.95 Million | +69.65% |
| 2004-12-31 | $7.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MDxHealth SA ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39050282117.0% over the analyzed period, potentially due to dividend distributions or operating losses.
MDxHealth SA ADR Net Assets Breakdown (December 2025)
MDxHealth SA ADR net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $219.21 Million | % |
| Other Comprehensive Income | $18.55 Million | % |
| Other Components | $153.18 Million | % |
| Total Equity | $-12.09 Million | 100.00% |
MDxHealth SA ADR Competitors by Market Cap
The table below lists competitors of MDxHealth SA ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Paramount Gold Nevada Corp
NYSE MKT:PZG
|
$111.47 Million |
|
GalaxiaMoneytree Co.Ltd
KQ:094480
|
$111.57 Million |
|
Heidelberg Pharma AG
F:HPHA
|
$111.58 Million |
|
Stellar Resources Ltd
AU:SRZ
|
$111.59 Million |
|
Bajaj Healthcare Limited
NSE:BAJAJHCARE
|
$111.44 Million |
|
Ice Make Refrigeration Limited
NSE:ICEMAKE
|
$111.42 Million |
|
Clal Industries and Beverages Ltd
TA:CLBV
|
$111.42 Million |
|
Business Alignment Public Company Limited
BK:BIZ
|
$111.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MDxHealth SA ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,841,000 to -12,094,000, a change of -26,935,000 (-181.5%).
- Net loss of 33,519,000 reduced equity.
- Other comprehensive income increased equity by 19,169,000.
- Other factors decreased equity by 12,585,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.52 Million | -277.15% |
| Other Comprehensive Income | $19.17 Million | +158.5% |
| Other Changes | $-12.59 Million | -104.06% |
| Total Change | $- | -181.49% |
Book Value vs Market Value Analysis
This analysis compares MDxHealth SA ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $18.77 | $2.17 | x |
| 2005-12-31 | $26.15 | $2.17 | x |
| 2006-12-31 | $49.20 | $2.17 | x |
| 2007-12-31 | $46.04 | $2.17 | x |
| 2008-12-31 | $38.38 | $2.17 | x |
| 2009-12-31 | $20.44 | $2.17 | x |
| 2010-12-31 | $10.82 | $2.17 | x |
| 2011-12-31 | $8.53 | $2.17 | x |
| 2012-12-31 | $7.26 | $2.17 | x |
| 2013-12-31 | $8.17 | $2.17 | x |
| 2014-12-31 | $6.84 | $2.17 | x |
| 2015-12-31 | $10.72 | $2.17 | x |
| 2016-12-31 | $11.45 | $2.17 | x |
| 2017-12-31 | $8.72 | $2.17 | x |
| 2018-12-31 | $9.05 | $2.17 | x |
| 2019-12-31 | $3.15 | $2.17 | x |
| 2020-12-31 | $0.70 | $2.17 | x |
| 2021-12-31 | $3.85 | $2.17 | x |
| 2022-12-31 | $0.59 | $2.17 | x |
| 2023-12-31 | $0.28 | $2.17 | x |
| 2024-12-31 | $0.30 | $2.17 | x |
| 2025-12-31 | $-0.24 | $2.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MDxHealth SA ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.07%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-131.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -99.96% | -1338.66% | 0.06x | 1.24x | $-7.75 Million |
| 2005 | -42.44% | -138.98% | 0.22x | 1.41x | $-6.27 Million |
| 2006 | -23.04% | -265.90% | 0.08x | 1.15x | $-13.95 Million |
| 2007 | -29.23% | -377.70% | 0.07x | 1.17x | $-19.52 Million |
| 2008 | -31.22% | -337.04% | 0.08x | 1.20x | $-18.73 Million |
| 2009 | -76.07% | -561.26% | 0.10x | 1.32x | $-23.18 Million |
| 2010 | -76.97% | -325.43% | 0.18x | 1.34x | $-12.40 Million |
| 2011 | -61.37% | -258.54% | 0.18x | 1.30x | $-10.47 Million |
| 2012 | -74.08% | -241.36% | 0.25x | 1.25x | $-13.47 Million |
| 2013 | -65.92% | -214.12% | 0.26x | 1.20x | $-18.63 Million |
| 2014 | -64.17% | -132.90% | 0.37x | 1.30x | $-17.63 Million |
| 2015 | -32.70% | -82.86% | 0.30x | 1.30x | $-18.90 Million |
| 2016 | -24.98% | -44.11% | 0.44x | 1.28x | $-18.45 Million |
| 2017 | -28.22% | -30.33% | 0.69x | 1.34x | $-16.64 Million |
| 2018 | -62.26% | -114.51% | 0.43x | 1.26x | $-37.66 Million |
| 2019 | -218.52% | -365.72% | 0.29x | 2.06x | $-45.07 Million |
| 2020 | -490.03% | -155.27% | 0.58x | 5.45x | $-29.25 Million |
| 2021 | -61.84% | -130.41% | 0.30x | 1.60x | $-33.69 Million |
| 2022 | -472.83% | -118.86% | 0.31x | 12.79x | $-44.98 Million |
| 2023 | -597.95% | -61.40% | 0.54x | 17.92x | $-43.82 Million |
| 2024 | -256.51% | -42.28% | 0.57x | 10.60x | $-39.55 Million |
| 2025 | 0.00% | -31.07% | 0.73x | 0.00x | $-32.31 Million |
Industry Comparison
This section compares MDxHealth SA ADR's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $642,049,271
- Average return on equity (ROE) among peers: -86.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MDxHealth SA ADR (MDXH) | $-30.40 Million | -99.96% | N/A | $111.46 Million |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $43.76 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $1.66 Million | -167.28% | 1.68x | $3.63 Million |
| Applied DNA Sciences Inc (APDN) | $-1.47 Million | 0.00% | 0.00x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.61 Million | -317.61% | 3.51x | $222.10 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $14.35 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $167.75 Million | -24.78% | 0.80x | $4.66 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $96.42 Million |
| CareDx Inc (CDNA) | $465.88 Million | -6.58% | 0.22x | $2.59 Billion |
| Check Cap Ltd (CHEK) | $41.31 Million | -46.25% | 0.10x | $9.42 Million |
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more